About inotiv - NOTV
Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
NOTV At a Glance
Inotiv, Inc.
2701 Kent Avenue
West Lafayette, Indiana 47906-1382
| Phone | 1-765-463-4527 | Revenue | 490.74M | |
| Industry | Miscellaneous Commercial Services | Net Income | -108,445,000.00 | |
| Sector | Commercial Services | Employees | 2,075 | |
| Fiscal Year-end | 09 / 2025 | |||
| View SEC Filings |
NOTV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.09 |
| Price to Book Ratio | 0.259 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 63.739 |
| Enterprise Value to Sales | 0.953 |
| Total Debt to Enterprise Value | 0.952 |
NOTV Efficiency
| Revenue/Employee | 236,500.723 |
| Income Per Employee | -52,262.651 |
| Receivables Turnover | 6.337 |
| Total Asset Turnover | 0.578 |
NOTV Liquidity
| Current Ratio | 1.373 |
| Quick Ratio | 0.913 |
| Cash Ratio | 0.18 |
NOTV Profitability
| Gross Margin | 11.015 |
| Operating Margin | -10.144 |
| Pretax Margin | -26.646 |
| Net Margin | -22.098 |
| Return on Assets | -12.774 |
| Return on Equity | -49.332 |
| Return on Total Capital | -17.615 |
| Return on Invested Capital | -17.093 |
NOTV Capital Structure
| Total Debt to Total Equity | 261.063 |
| Total Debt to Total Capital | 72.304 |
| Total Debt to Total Assets | 52.901 |
| Long-Term Debt to Equity | 252.083 |
| Long-Term Debt to Total Capital | 69.817 |